Other large deals this year indicate similar dynamics between PE firms and corporations.

Warburg Pincus sold Bausch & Lomb to Valeant Pharmaceuticals ( VRX) for $8.7 billion, in a deal that tabled an IPO of the eye care specialist. Rockwell Collins ( ROC) and Cardinal Healthcare ( CAH) have also participated in large acquisitions of PE portfolio investments this year.

Yankee Candle's acquisition by Jarden, while unique given Franklin involvement, may stand out as the transaction executives and investors pay attention to heading into 2014. Given a strong investor reaction to the deal, it won't come as a surprise to see other corporations look to PE portfolio's for their next acquisition.

Madison Dearborn, through a spokesperson, declined to comment.

-- Written by Antoine Gara in New York.

If you liked this article you might like

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jim Cramer -- 'The Real Market's Healthier,' So Ignore the Bears

Jim Cramer -- Buy Bank of America Over Citigroup, Wells Fargo

Jim Cramer: I'm Bullish on Stronger Newell Rubbermaid

Jim Cramer Is Bullish on Newell Rubbermaid Following Merger With Jarden